Hyperuricemia-Pipeline Review, H1 2015

Hyperuricemia-Pipeline Review, H1 2015

  • Products Id :- GMDHC6615IDB
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hyperuricemia-Pipeline Review, H1 2015


Global Markets Direct's, 'Hyperuricemia-Pipeline Review, H1 2015', provides an overview of the Hyperuricemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperuricemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Hyperuricemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hyperuricemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hyperuricemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hyperuricemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hyperuricemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hyperuricemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hyperuricemia Overview 7

Therapeutics Development 8

Pipeline Products for Hyperuricemia-Overview 8

Pipeline Products for Hyperuricemia-Comparative Analysis 9

Hyperuricemia-Therapeutics under Development by Companies 10

Hyperuricemia-Therapeutics under Investigation by Universities/Institutes 11

Hyperuricemia-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Hyperuricemia-Products under Development by Companies 15

Hyperuricemia-Products under Investigation by Universities/Institutes 16

Hyperuricemia-Companies Involved in Therapeutics Development 17

AstraZeneca PLC 17

CymaBay Therapeutics, Inc. 18

Kissei Pharmaceutical Co., Ltd. 19

LG Life Sciences, Ltd. 20

Nippon Chemiphar Co., Ltd. 21

Polaris Pharmaceuticals, Inc. 22

Takeda Pharmaceutical Company Limited 23

Teijin Pharma Limited 24

Hyperuricemia-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

arhalofenate-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

febuxostat-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

febuxostat XR-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

JPH-367-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

KGO-2142-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

KGO-2173-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

KUX-1151-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

LC-350189-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

NC-2500-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

pegadricase-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

RDEA-3170-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

XEN-102-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Hyperuricemia-Recent Pipeline Updates 51

Hyperuricemia-Dormant Projects 54

Hyperuricemia-Discontinued Products 55

Hyperuricemia-Product Development Milestones 56

Featured News & Press Releases 56

Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat 56

Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric 57

Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat 57

Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat 58

Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea 59

May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan 59

Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67 60

Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan 60

Oct 27, 2010: Teijin Pharma Launches TMX-67 In Canada 61

Mar 09, 2010: Menarini Launches ADENURIC (Febuxostat) In Europe 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

Number of Products under Development for Hyperuricemia, H1 2015 8

Number of Products under Development for Hyperuricemia-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Hyperuricemia-Pipeline by AstraZeneca PLC, H1 2015 17

Hyperuricemia-Pipeline by CymaBay Therapeutics, Inc., H1 2015 18

Hyperuricemia-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 19

Hyperuricemia-Pipeline by LG Life Sciences, Ltd., H1 2015 20

Hyperuricemia-Pipeline by Nippon Chemiphar Co., Ltd., H1 2015 21

Hyperuricemia-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 22

Hyperuricemia-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 23

Hyperuricemia-Pipeline by Teijin Pharma Limited, H1 2015 24

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Stage and Target, H1 2015 27

Number of Products by Stage and Mechanism of Action, H1 2015 29

Number of Products by Stage and Route of Administration, H1 2015 31

Number of Products by Stage and Molecule Type, H1 2015 33

Hyperuricemia Therapeutics-Recent Pipeline Updates, H1 2015 51

Hyperuricemia-Dormant Projects, H1 2015 54

Hyperuricemia-Discontinued Products, H1 2015 55

List of Figures

Number of Products under Development for Hyperuricemia, H1 2015 8

Number of Products under Development for Hyperuricemia-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Top 10 Targets, H1 2015 26

Number of Products by Stage and Top 10 Targets, H1 2015 27

Number of Products by Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Top 10 Routes of Administration, H1 2015 30

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31

Number of Products by Top 10 Molecule Types, H1 2015 32

Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

AstraZeneca PLC

CymaBay Therapeutics, Inc.

Kissei Pharmaceutical Co., Ltd.

LG Life Sciences, Ltd.

Nippon Chemiphar Co., Ltd.

Polaris Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

Teijin Pharma Limited

Hyperuricemia Therapeutic Products under Development, Key Players in Hyperuricemia Therapeutics, Hyperuricemia Pipeline Overview, Hyperuricemia Pipeline, Hyperuricemia Pipeline Assessment

select a license
Single User License
USD 2000 INR 142960
Site License
USD 4000 INR 285920
Corporate User License
USD 6000 INR 428880



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com